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ABSTRACT 
 
Human saliva is a fluid with many biological functions, and essential for the maintenance of oral 
health. Several studies report local and systemic biomarkers appearing in saliva, including 
electrolytes, blood products, enzymes and tissue destruction molecules, inflammatory markers as well 
as proteins putatively associated with different diseases. However, the clinical utility of salivary 
diagnostics for the assessment of oral and systemic disease remains elusive. The general aim of this 
project was to investigate the utility of salivary biomarkers for diagnostic potential of oral- and 
systemic diseases in large populations. 
This thesis consists of two different projects:  
(i). Skåne cohort - A cross-sectional study (Studies I and II): 451 individuals were randomly selected 
and enrolled for these investigations, including 51% women. All participants were asked to complete 
a questionnaire, a medical history was taken, a clinical examination was made and stimulated saliva 
samples were collected.  
(ii). PAROKRANK sub-cohort (Periodontal disease and the relation to myocardial infarction) 
(Studies III and IV): A case-control study comprising 400 subjects. In total 200 consecutive patients 
with a first acute myocardial infarction (AMI) admitted to coronary care units in Sweden from May 
2010 to December 2011, and 200 controls without previous AMI, matched for age, gender, residential 
area were included during the same time period. Dental examinations were performed, blood and 
stimulated saliva samples were collected eight to ten weeks after the myocardial infarction (MI). 
Matched controls were examined within one to two weeks after the MI patients.  
Study I: The aim of this study was to investigate if selected salivary biomarkers could be used for 
epidemiological studies for detection of periodontitis. Our findings showed that patients with severe 
periodontitis had elevated salivary concentrations of interleukin (IL) -1β (IL-1β) and matrix 
metalloproteinase (MMP) -8 (MMP-8), as well as and increased ratio of MMP-8/ tissue inhibitor of 
metalloproteinase-1 (TIMP-1).   
Study II: The aim of this study was to investigate if certain salivary biomarkers could be used for 
detection of common systemic inflammatory diseases. The results of our study showed that salivary 
IL-8 concentrations were higher in patients with bowel disease and subjects who had experience of 
tumor diseases. MMP-8 levels were elevated in saliva from patients with diabetes, muscle and joint 
diseases or previously had undergone cardiac surgery. 
Study III: The aim of this study was to investigate whether salivary concentrations of selected 
cardiovascular biomarkers could be used to identify patients with a previous MI and whether such 
markers, in plasma and saliva, were related to periodontal status. There was no difference between 
participants with or without MI in regards of N-terminal prohormone of brain natriuretic peptide (NT-
pro BNP) and growth differentiation factor-15 (GDF-15) levels in saliva. However, cystatin C, NT-
pro BNP and GDC-15 levels were higher in MI patients with other co-morbidities. The levels of 
cystatin C were lower in saliva from patients with MI. GDF-15 levels correlated with periodontal 
status in both groups. Further, there was no correlation between plasma and saliva levels. 
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Study IV: The aim of this study was to explore the levels of the inflammatory markers, MMP-8, 
MMP-9, TIMP-1 and myeloperoxidase (MPO) in saliva with regards to previous MI and periodontal 
disease. The analyzed biomarkers correlated significantly with each other and most of the periodontal 
parameters in both study groups. Salivary MMP-8 and MPO levels were significantly higher in non-
MI subjects.  
In conclusion, the findings in this project indicates that certain salivary biomarkers have the potential 
to be used for screening purposes in epidemiological studies related to both oral and systemic 
diseases. In addition, the selected salivary biomarkers in our studies could be seen as markers for 
increased local and systemic inflammation.  
 
 
Key words: Interleukin-1β, -6 and -8, Cystatin C, Growth differentiation factor-15, Matrix 
metalloproteinases-8 and -9, Myeloperoxidase, Myocardial infarction, Periodontal disease, Plasma, 
Saliva, Tissue inhibitor of metalloproteinase-1  
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INTRODUCTION 
 
 
HUMAN SALIVA  
 
Whole saliva is a unique biological fluid and it has been described as the “mirror of the body”. Saliva 
is composed mainly of water (98%) and about 2% other compounds, such as minerals, electrolytes, 
hormones, antibacterial compounds, mucins, various enzymes, immunoglobulins and cytokines (1). 
Primary saliva is produced by major and minor salivary glands essentially. Salivary secretion takes 
place mainly from the acinar and ductal cells of the salivary glands (2). Whole saliva is not a 
homogeneous fluid and is made up of secretions from a number of sources, including fluid from the 
extrinsic glands and intrinsic glands, epithelial cell secretions, and the gingival crevicular fluid. In 
addition, capillaries passing through the salivary glands facilitate the entry of analytes from the 
systemic circulation into saliva (1). 
 
THE SALIVARY GLANDS  
 
The salivary gland systems in humans are divided into two separate exocrine groups: major and minor 
glands. Major salivary glands are bilateral paired glands and include parotid (PG), submandibular 
(SMG), and sublingual glands (SLG) [Figure 1]. There are numerous minor salivary glands as well. 
Salivary glands are associatedwith ducts and the gland is internally divided into lobules. Nerves and 
blood vessels enter the glands at the hilum and steadily branch out into the lobules. The lumina are 
formed by intercalated ducts in the duct system, and ending up in the secretory ducts. Human salivary 
glands terminate in the mouth. All salivary glands together produce around 90% of the total volume 
of saliva (3). Organogenesis of salivary glands, include multiple cell types, such as epithelial, 
myoepithelial, mesenchymal, neuronal, lymphatic, and endothelial cells. The interactions among 
above mentioned cell types occur during the initiation and development of the salivary epithelium (4). 
 
Parotid glands (PG) 
 
The largest salivary gland is PG and is found wrapped around the mandibular ramus. Mainly this 
paired gland secrets saliva of serous nature and enters the oral cavity via Stensen's duct (4). 
 
Submandibular glands (SMG)  
 
The SMG is also a paired gland located beneath the lower jaw, superior to the digastric muscles. SMG 
secretion produces a mixture of serous  and mucus fluid, entering the oral cavity via Wharton's ducts, 
and about 70% of saliva production in the oral cavity is produced by the SMG, although SMG is 
much smaller than the PG (4). 
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Sublingual gland (SLG) 
 
The paired SLG is located beneath the tongue, anterior to the SMG, and contributes to 5% of saliva 
production in the mouth (4). The main secretion is mucus in nature. Unlike the PG and SMG, the 
ductal system of the SLG do not have striated ducts, and exit from 8-20 excretory ducts (4). 
 
Minor salivary glands 
 
In the oral cavity within the submucosa, there are over 600 minor salivary glands. The size of them is 
varies between 1‒2mm in diameter and unlike the other glands. The minor glands are not 
encapsulated by connective tissues, only surrounded by it. Minor salivary glands have a common 
excretory duct together with another gland or they have their own excretory duct (4). 
 
Von Ebner's glands 
 
Von Ebner's glands are found in circumvallate papillae of the tongue. They secrete saliva of serous 
nature and facilitate the perception of taste (4). 
 
 
 
 
 
 
Figure 1: The major salivary glands: parotid gland, submandibular gland, 
and sublingual glands (5). Reproduced by permission of SAGE 
Publications. 
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INNERVATION ROUTES OF SALIVARY GLANDS  
 
 
It has been known for the last 150 years that nervous to the salivary glands control the secretion of 
saliva, and both parasympathetic and sympathetic arms of the autonomic nervous system innervate the 
salivary glands resulting in increased amylase output and volume flow (6). 
 
Parasympathetic innervation to the salivary glands: Innervation of the PG occurs via the cranial 
nerve IX: the glossopharyngeal nerve. The SMG and SLG obtain their parasympathetic input from the 
cranial nerve VII: facial nerve trough the submandibular ganglion (3). 
 
Sympathetic innervation to the salivary glands: The sympathetic salivary centers are located in the 
upper thoracic segments of the spinal cord and the sympathetic innervation of the salivary glands 
occurs through the thoracic segments T1-T3, leading to an increase in saliva secretion. Additionally, 
the sympathetic nervous system affects salivary gland secretions indirectly by innervating the blood 
vessels, which supply the glands (3). 
 
The ultimate results, of both parasympathetic and sympathetic stimuli, are an increase in salivary 
gland secretion but it is the parasympathetic system that provides the main control of the salivary 
glands (3). The saliva coming from the parasympathetic system is watery, contains fewer proteins and 
has a high flow rate, whereas sympathetic regulation contributes saliva with higher viscosity due to 
mucin-rich saliva with a low flow rate (7).   
 
STIMULATED VERSUS UNSTIMULATED WHOLE SALIVA 
 
 
Unstimulated whole saliva, also called resting saliva, is composed mainly of SMG saliva together 
with saliva from SLG and minor salivary glands. The characteristics of unstimulated saliva are that it 
is more viscous and is mucin-rich (7).  
Normal unstimulated saliva secretion: > 0.25 ml/min 
Hyposalivation: < 0.1 ml/min 
Stimulated whole saliva is mainly composed of PG saliva and to some extent saliva from the SMG 
that is produced upon stimulation. Characteristics of stimulated saliva reveal that it is thin, watery and 
amylase-rich (7).  
Normal stimulated saliva secretion: > 1 ml/min   
Hyposalivation: < 0.7 ml/min 
 
 
MAIN FUNCTIONS OF SALIVA  
 
Whole saliva has multiple functions, include rinsing, solubilization of food substances, food and 
bacterial clearance, lubrication of soft tissues, bolus formation, dilution of detritus, swallowing, 
speech, facilitation of mastication, and through a number of mechanisms saliva protects the teeth, all 
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of which are related to its fluid characteristics and specific components. In addition, saliva 
components contribute to mucosal coating, digestion and antibacterial defence (8).  
 
Digestion  
Saliva is essential for the normal mastication of food, for moistening food and helping to create a food 
bolus. The lubricating function of saliva allows the food bolus to be passed easily from the mouth into 
the esophagus. Food intake can be difficult and uncomfortable if there is a lack of salivary lubrication. 
Saliva contains important enzymes, such as salivary amylase involved in the first conversion of 
polysaccharide carbohydrates and breakdown of starch into simpler sugars that can later be absorbed 
or further broken down in the small intestine, and lingual lipase, which initiates the breakdown of 
lipids and has a protective function, helping to prevent bacterial build-up on the teeth and washing 
away adhered food particles (7, 9). 
 
Disinfectants                                                                                                                                
It is well known that saliva contains natural disinfectants, such as locally and systemically produced 
immunoglobulins, lysozyme, lactoferrin, peroxidase, mucins, and a collection of antimicrobial 
peptides (10). Salivary immunoglobulins, in particular secretory immunoglobulin A (sIgA) is the 
dominant form in oral mucous secretions, unlike in systemic circulation where immunoglobulin G 
(IgG) is more abundant (10-11). Secretory IgA in the oral cavity acts as a first line of defense in the 
innate immune arsenal by immobilizing antigens, such as bacteria (12). IgG enters the oral cavity 
through the salivary glands, simply passing through the epithelium but during oral inflammatory 
conditions, such as periodontal disease, monomeric IgG enters saliva mainly via gingival crevicular 
fluid (GCF) and thus not through the salivary glands (13).  
Antimicrobial peptides (AMPs), a family of antimicrobial agents, a major component of the innate 
defense mechanism, have been identified in most physiological fluids and in an exposed environment, 
such as the mouth, where they play an essential role in the balance between health and disease (14).  
Peroxidase and lysozymes are common in different secretions, such as saliva and tears.  They have 
strong antimicrobial activity, which cause damage to the cell walls of bacteria by hydrolysis (15).  
Mucins are glycoproteins that are viscous and rather insoluble. The main role of mucins is to protect 
the soft tissues of the oral cavity from dehydration and mechanical damages. In addition, mucins are 
responsible for the selective adhesion of bacterial and fungal agents and help to prevent biofilm 
formation. They also protect both soft and hard tissues from abrasion damage by forming a lubricating 
coating on tissues (15).  
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PERIODONTAL DISEASE  
 
The terminology of periodontal disease encompasses gingivitis, chronic periodontitis and aggressive 
periodontitis according to the International Workshop for the Classification of Periodontal Disease 
(1999). There are numerous of subcategories as well: periodontitis as a manifestation of systemic 
disease, necrotizing periodontal disease, abscesses of the periodontium, periodontitis associated with 
endodontic lesions, and development of acquired deformities and conditions (16).  
 
 
Gingivitis 
 
Gingivitis is an inflammatory condition in the periodontal tissue caused by accumulation of dental 
plaque but it does not include any type of soft tissue- and bone loss surrounding the teeth. There are 
two forms of gingivitis: plaque induced gingivitis and non-plaque induced gingivitis. The most 
common type is plaque induced gingivitis with the presence of inflammation in the gum. Clinical 
features of induced gingivitis are redness, swelling, and bleeding, this condition is reversible and can 
usually be reversed by treatment and adequate oral care maintenance (16).  
 
Chronic Periodontitis  
 
Periodontitis is a chronic inflammatory disorder, associated with complex of interactions between 
periodontal bacteria, the host inflammatory response, genetic, environmental and behavioral risk 
factors. The most common form of the disease is plaque induced periodontitis, characterised by 
gingival inflammation, release of different pro-inflammatory cytokines, destruction of periodontal 
tissues and alveolar bone. Clinical signs of periodontitis are pocket formation, swollen and bleeding 
gingiva. Chronic periodontitis is a slowly progressing disease but it can include episodes of more 
rapid progress. The supporting collagen of the periodontium degenerates, resorbing alveolar bone, and 
the gingival epithelium migrates along the tooth surface and ultimately forming a periodontal lesion. 
Finally, the outcome of untreated periodontitis is tooth loss (17, 18) [Figure 2]. 
 
In this condition, predominantly anaerobic bacteria are the initiating agents, the red complex 
essentially: Porphromonas gingivalis, Tannerella forsythia and Treponema denticola, together with 
Aggregatibacter actinomycetemcomitans and some members of the orange complex, such as 
Prevotella intermedia (19). The process starts with bacterial adhesion and colonization of the teeth 
surface and accumulation of the dental biofilm. Periodontal pathogens have the ability to penetrate the 
gingival epithelium and release endotoxins and cytotoxic enzymes, and by-products that could induce 
breakdown of the extracellular matrix (ECM). Bacterial toxins activate several proteolytic enzymes 
and an inflammatory response. The damage caused by pathogens initiate directly or indirectly by 
trigging host-mediated responses that finally lead to tissue breakdown. In a periodontal lesion, 
neutrophilc granulocytes act first, followed by antibody activation of lymphocytes and monocytes 
(18). 
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Risk factors of periodontitis    
 
Periodontitis is considered a complex interaction of bacterial infection, host response and other 
important factors. Common risk factors associated with periodontitis, include presence and amount of 
the periopathogens, smoking, genetics, obesity, osteoporosis, low dietary calcium and vitamin D, and 
poorly controlled diabetes (20).  
 
 
 
 
 
 
 
 
 
 
 
 
Periodontal diagnosis  
 
Diagnosis (Greek diágnōsis, examination/ analysis) is very important in terms of subsequent 
management of a patient’s disease / condition. Periodontal diagnosis is based upon clinical 
examination and radiographic assessments (16).  
The clinical examination features of periodontitis include the presence of dental plaque, bleeding on 
probing, probing pocket depth, furcation involvement, clinical attachment loss, tooth mobility and 
presence of calculus.  
The radiographic examination assesses the marginal bone level. 
 
Chronic periodontitis is divided into localized and generalized forms depending on the percentage of 
sites affected based on the results of both clinical and radiographic examinations (16).  
Localized periodontitis: up to 30% of the teeth are affected 
Generalized periodontitis: >30% of the teeth are involved 
Further, the severity of the disease is divided into three sub categories based to the amount of clinical 
attachment loss (16):  
Slight: 1‒2 mm 
Moderate: 3‒4 mm 
Severe:  ≥ 5 mm 
Figure 2: Model of pathogenesis of human periodontitis. PMNs: 
polymorphonuclears leukocytes, LPS: lipopolysaccharide, MMPs: matrix 
metalloproteinases (18) Reproduced by permission of John Wiley and Sons. 
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CARDIOVASCULAR DISEASE  
 
 
PREVALENCE OF CARDIOVASCULAR DISEASE 
 
Cardiovascular disease (CVD), including myocardial infarction (MI) is common in the adult 
population worldwide and a leading cause of mortality, accounting for half of all deaths. About 4 
million deaths (47 % of all deaths) are causes by CVD in the European population each year and 1.9 
million (40 %) within the European Union. In general, the mortality rate caused by CVD is higher in 
women (54 % of all deaths) than in men (43 % of all deaths). In Sweden, the percentage of deaths, 
which are from CVD follows: 41 % in women and 39 % in men (21). The incidence of acute MI 
(AMI) as well as the mortality rate after AMI has decreased over the past 20 years in Sweden (22, 23) 
[Figures 3 & 4]. This is explained by improved primary and secondary prevention, as well as of 
improved acute coronary care (22).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Age-standardized incidence of AMI per 100 000 individuals aged 20 years and above, 
by gender and year, 1988-2012.  Blue line: men; Red line: women (22) Reproduced by 
permission of The National Board of Health and Welfare (Socialstyrelsen) 
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Myocardial infarction (MI) 
 
An event of acute coronary syndromes (ACS) is mainly based on clinical- and electrocardiogram 
(ECG) findings and serological biomarkers, and is divided into three different entities; ST-elevation 
MI, non-ST-elevation MI or unstable angina. An AMI occurs when the coronary artery oxygen-rich 
blood flow to a part of the heart muscle suddenly becomes blocked leading to myocardial necrosis, 
with leakage of myocardial muscle proteins into the blood (24). According to the third universal 
definition,  a MI is based on patient symptoms, specific biomarker elevation, ischemic ECG changes, 
and imaging evidence. Pathologically MI is defined as myocardial cell death. The clinical diagnosis 
criteria of MI include the following: a rise and/or fall of cardiac biomarker values, such as Troponin, 
symptoms of ischemia, detection of pathological Q waves in the ECG, finding of ST-segment 
changes, loss of viable myocardium or regional wall motion abnormality and angiographic 
identification of an intracoronary thrombus (25). There are five types of MIs and the classification is 
based on pathological, clinical, and prognostic differences (25) [Table 1]. 
 
Table 1: The types of MIs  
Type 1: Spontaneous MI 
Type 2: MI secondary to an ischemic imbalance 
Type 3: MI resulting in death when biomarker values are unavailable 
Type 4a: MI related to percutaneous coronary intervention 
Type 4b: MI related to stent thrombosis 
Type 4c: MI related to restenosis 
Type 5: MI related to coronary artery bypass grafting 
 
 
Figure 4: Development of mortality for patients with MI covering all ages, 1995-2012. 
(23)  Reproduced by permission of SWEDHEART 
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Atherosclerosis 
 
Atherosclerosis is a disorder related to aging with a chronic inflammatory component. Inflammation 
is presumably involved in the initiation, progression and rupture of a coronary plaque ultimately 
leading to an infarction. An inflammatory reaction begins against endothelial cells and other 
components of the artery wall, and the inflammation sites attract accumulation of different cells, such 
as macrophages, T and B lymphocytes and mast cells [Figure 5]. Atherosclerosis is a multifactorial 
disease and involvement of different pathogens in the atherosclerosis process has  also been suggested 
based on findings from  epidemiological studies, such as Chlamydia pneumonia, Helicobacter pylori, 
periodontal pathogens (Porphromonas gingivalis, Prevotella intermedia and Aggregatibacter 
actinomycetemcomitans) and Cytomegalovirus (26-29).  
 
 
 
 
 
 
 
 
 
 
Risk factors of myocardial infarction 
 
There are several known risk factor for MI. In fact it has been shown that nine factors can explain 
about 90% of all the risks for MI in several parts of the world. The INTERHEART study, a case-
control study of MI, conducted in 52 countries, comprising a total number of 29 972 subjects (15 152 
cases and 14 820 controls), revealed that about 90% of the risk associated with a myocardial 
infarction was explained by nine modifiable risk factors: smoking, hypertension, diabetes, abdominal 
obesity, psychosocial factors, low consumption of fruit/vegetables and alcohol, level of physical 
activity, and enhanced ApoB/ApoA1 ratio (31).  
 
Association between periodontal disease and cardiovascular disease 
 
The association between periodontal disease and CVD has been discussed since late 80’s (32). A large 
number of epidemiological studies have shown an association between periodontitis and CVD (33), 
but a causal relationship has yet to be established (34).  The link between periodontitis and CVD 
could be explained by periodontitis has effects to elevate systemic inflammation and endothelial 
dysfunction (33). Furthermore, pathogens derived from the oral biofilm involved in the pathogenesis 
of atheroma plaque formation (35). Previous studies showing improved oral hygiene and periodontal 
treatment may contribute to the prevention of atherosclerosis (36).  
Figure 5: An illustration of development of atherosclerosis (30) Reproduced and 
modified by permission of Wolters Kluwer Health. 
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BIOMARKERS IN GENERAL  
 
There are different definitions of a biomarker in the literature. The National Institutes of Health (NIH) 
defined a biomarker as “A characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic 
intervention” (37). According to the World Health Organization (WHO), the definition of a biomarker 
is following "any substance, structure, or process that can be measured in the body or its products and 
influence or predict the incidence of outcome or disease" (38). Biomarkers are usable for diagnostics, 
monitoring disease prognosis, and disease monitoring and prediction. The term ‘biomarker’ is 
relatively new but it has have been used in preclinical research and clinical diagnosis for some 
considerable time (39). Examples of biomarkers include pulse and blood pressure through basic 
chemistries to more complex laboratory tests of biological fluids, cells and other tissues. In medicine, 
a biomarker can be a substance that is introduced into an organism as a means to examine organ 
function or other aspects of health. The human genome encompasses the code for the expressed gene 
products, including the final mature protein products that are termed proteoforms. Proteins are 
responsible for the majority of biological functions and they represent an obvious target for biomarker 
discovery studies (40).  
More specifically, biomarkers are important mediators of inflammation, and they are associated with 
pathogenesis of many inflammatory diseases. Biomarkers are in clinical use, as non-invasive 
diagnostic markers, for disease prognosis and to monitor treatment response. 
 
 
Inflammatory biomarkers 
 
Many inflammatory biomarkers associated with oral diseases have been analyzed in saliva, such as, 
interleukin (IL) -1β, IL-6 and IL-8, tumour necrosis factor-alpha (TNF-α), matrix metalloproteinases 
(MMP) -8 and -9, TIMP-1, and myeloperoxidase (MPO) (1, 41, 42). Inflammatory mediators are 
released from different cells due to inflammatory conditions.  
 
IL-1β is a pro-inflammatory cytokine that participates in immune defense against infection. The IL-1 
cytokine family comprises eleven members, amongst which IL-1α and IL-1β are most studied. Both 
IL-1α and β have a 25% of sequence similarity at the protein level, despite being products of different 
genes. These proteins are produced by several types of cells, such as monocytes, macrophages, 
fibroblasts, and dendritic cells. The functional outcome of IL-1β depends upon variables, such as 
concentration, duration of expression, and timing among stimuli. IL-6 has both pro- and anti-
inflammatory properties, and is secreted by neutrophils, keratinocytes, fibroblasts and endothelial 
cells. The pro- inflammatory properties of IL-6 are to induce the acute-phase responses during 
inflammation. IL-6 appears to be the main mediator in various inflammatory diseases, such as renal 
disease and rheumatoid arthritis. As an anti-inflammatory cytokine, IL-6 inhibits the effects of TNF- 
and IL-1. IL-8 is a member of the chemokine family, and produced by macrophages, epithelial cells 
and fibroblasts upon inflammatory stimulation. Primary function of IL-8 is to recruit neutrophils to 
the site of inflammation to phagocytose the antigen. Amongst all chemokines, IL-8 has significant 
potential as aprognostic and / or predictive cancer biomarker, for several clinical conditions, as well 
as, for inflammatory conditions. TNF-α is a pro-inflammatory cytokine addition to being involved in 
local and systemic inflammation. It is a member of the group of cytokines that stimulate the acute 
phase reaction. It is produced by macrophages, although it can be produced by other cell types like 
lymphoid cells, mast cells, endothelial cells, and fibroblasts. The primary role of TNF- is in the 
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regulation of immune cells, it has capacity to induce fever, to induce apoptotic cell death, to induce 
sepsis, and induce inflammation (43-45).  
 
MMPs are enzymes that have the ability to degrade almost all ECM proteins. Typically, they are 
secreted by different cell types, such as fibroblasts, osteoblasts, endothelial cells, macrophages, 
neutrophils and lymphocytes (46). MMPs have different roles depending upon the condition. In 
normal physiological processes, MMPs take part in tissue development, remodelling and wound 
healing (47). In addition, MMPs, by processing various non-matrix bioactive substrates, have an 
anti-inflammatory (defensive) role and act on pathogenic (tissue destructive) of large number of 
different tissue destructive diseases and conditions (48). 
 
There are 28 members of MMPs. 23 are found in human beings, and they are genetically distinct but 
structurally related. All MMPs are classified into six different subfamilies and the most efficient 
MMPs are collagenases since these cleave not only collagens I, II, and III, also other ECM molecules 
and various proteins. The second group is gelatinases and the main substrate of this subfamily is 
gelatin. Gelatinases cleave ECM molecules and basement membrane proteins (49, 50). The activation 
of MMPs can take place in different ways and there are several mechanisms that control MMP 
activity: enzyme inhibition, inflammatory cytokines, growth factors and hormones (51).  
 
There are two major types of endogenous MMP inhibitors: Tissue inhibitors of matrix 
metalloproteinases (TIMPs) and  macroglobulins. The four different types of TIMPs are known: 
TIMP-1, -2, -3, and -4. The molecular structure of TIMPs, divided into two subdomains: C- and N-
terminals, dictate the function properties of the molecule. The N- terminal domain directs the 
pathological activities of MMPs, by blocking the Zn
2+
 reaching the active site of MMP- molecule. 
The extent of inhibition differs between different MMP molecules (51). The balance between 
TIMPs and MMPs is challenging to maintain in normal physiological conditions in tissues (52).  
 
 
MMP-8, also known as collagenase-2 or neutrophil collagenase, is particularly related to 
inflammatory conditions. MMP-8 is expressed mainly by neutrophils but also by several other cells, 
such as macrophages, plasma cells, T-cells, fibroblasts, chondrocytes and epithelial cells. It is stored 
in intracellular granules, and secretd and released in response to extracellular stimuli (53). MMP-8 
is secreted as an inactive pro-enzyme and activation can be initiated by reactive trypsin or other 
MMPs (54, 55). TIMP-1 is the major inhibitor of MMP-8. Elevated MMP-8 concentrations are 
found in inflammatory conditions, such as periodontontal disease, dental caries, atherosclerosis, and 
cancer (56-58). 
 
MPO is an enzyme released from PMN granules, is strongly associated with on-going inflammation 
(59), and has widely been used as an inflammatory marker of both acute and chronic conditions 
(60,61). The important role of MPO is to inactivate TIMPs and pathogenic bacteria by generating 
reactive oxygen species, as well as oxidatively activating latent proMMP-8 and -9 (59, 62). 
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Biomarkers of periodontal disease  
 
Periodontal disease diagnosis is based upon clinical examination and radiographical assessments of 
periodontal tissues but tools for diagnosis, evaluation of severity and prognosis of periodontal disease 
are currently insufficient. Based on this statement, sensitive and disease-specific salivary biomarkers 
to complement regular clinical examinationa are of interest. A number of inflammatory biomarkers 
(IL-1β, IL-6, and IL-8, MMP-8, TIMP-1 and TNF-α) associated with oral diseases, such as dental 
caries, gingivitis and periodontitis have been detected in saliva. Whole saliva contains local- and 
systemic derivative biomarkers, which raises the possibility of using saliva as a diagnostic medium for 
periodontal disease. (41, 42, 63, 64). In addition, the use of disease-specific biomarkers increases the 
specificity and sensitivity for obtaining accurate diagnostic and prognostic information. Elevated 
salivary levels of IL-1β and MMP-8 are significantly associated with severe periodontitis compared to 
healthy controls (41) [Figure 6]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers of cardiovascular disease  
 
In 1956, the first report on the use of cardiac biomarkers for MI was published, measuring aspartate 
aminotransferase (66). Since then improved diagnostic methods have been developed and since the 
year 2000 troponins are used to detect and define a MI (67). Biomarkers released from a myocardial 
injury of myocardial ischemia and necrosis, include cardiac troponins I (TnI) and T (TnT), creatine 
kinase-MB (CK-MB), total creatine kinase, myoglobin (MYO), N-terminal prohormone of brain 
natriuretic peptide (NT-pro BNP) and lactate dehydrogenase (68) [Figure 6]. Complimentary markers, 
such as Cystatin C and growth differentiation factor-15 (GDF-15) provide additional information for 
diagnosis, evaluation, risk assessment and prognosis of AMI patients (69-71).  
IL1β, MMP-8, TNF-α 
Figure 6: Salivary diagnosis: Periodontitis and Cardiovascular Disease (65) 
Reproduced and modified by permission of Future Medicine Ltd. 
IL1β, MMP-8, TNF-α 
 
Tn I & T, CK-MB, MYO 
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Cystatin C levels are used as a clinical test for kidney function, produced by all nucleated cells and 
released to the blood (72). Increased levels of cystatin C are reported to be a strong predictor of CVD 
in chronic kidney disease patients (71). Yamashita et al reported a significant correlation between 
cystatin C levels and cardio-ankle vascular index (a marker of early -stage arteriosclerosis) in female 
subjects without chronic kidney disease (73).  
GDF-15 is a novel emerging cardiovascular risk marker. It is well known that in healthy conditions, 
GDF-15 is expressed at low levels in all organs except the placenta but when it is comes to 
pathological conditions related to inflammation, tissue injury and remodeling, the expression of GDF-
15 increases rapidly. The main role of GDF-15 is to regulate inflammatory pathways in injured tissues 
(74).  Higher levels of GDF-15 have been found in patients with chronic heart failure (70, 75).  
NT-proBNP is synthesized and secreted from the cells of ventricular myocardium in response to 
pressure and volume overload of the heart.  NT-proBNP is a peptide and acts as a hormone, which 
dilates the blood vessels and increases diuresis. There are number of clinical settings in which NT-
proBNP levels are elevated, including acute and chronic heart failure, renal dysfunction and 
pulmonary disease, as well as, acute coronary syndrome (76). NT-proBNP is linked to prognosis and 
is a predictor of short and long term mortality in patients with heart failure, of future cardiac events 
and survival after AMI (69, 77).   
Tn I &Tn T have become the golden standard for diagnosis of AMI since cardiac troponins are highly 
tissue specific for the myocardium. Further, they act as regulatory proteins of the myocardium and are 
required for muscle contraction (68). Analyses of cardiac troponins are also very sensitive, thus 
allowing detection of small myocardial injuries (78).  
The use of saliva for diagnosis of AMI has been a popular area of interest and could potentially 
provide faster screening and verdicts. Floriano et al. reported that the use of a saliva-based Nano-
Biochip test together with ECG,  may provide a convenient and prompt screening method for cardiac 
events in pre-hospital stages for AMI patients. (79). In the same study the authors reported that 
cardiac enzymes such as CK-MB, MYO, TnI & T and inflammatory markers (C-reactive proteins, 
TNF-α, MMP-9 and MPO) in saliva were elevated in AMI patients (79).   
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SALIVA VERSUS BLOOD  
 
Blood: serum or plasma is traditionally and most frequently the source of measurable biomarkers. 
Saliva is a multifaceted oral fluid, like blood it contains numerous components, including enzymes, 
hormones, antibodies, cytokines, and growth factors. Blood sampling and analysis can often be 
expensive, problematic and physically invasive. Using saliva as a medium for biomarker development 
and assessment eases patient discomfort by convenience and a non-invasive method of diagnostic 
purpose for diseases/conditions. 
The advantages of saliva for the support of diagnostic potential include the following: 
 Non-invasive procedure: painless and reduced discomfort  
 Undemanding collection: saliva sampling can be done by anyone, including self-collection. 
 Cost effective procedure 
 Saliva is safer to handle, easier to store and ship than blood 
They are several favorable attributes of using saliva as a diagnostic fluid, thus saliva offers some 
distinct advantages in selected situations. Some of the mediators detected in serum or plasma are also 
found in saliva but the levels of these mediators are substantially diminished (80, 81).  
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OBJECTIVES 
 
The overall aim of this thesis was to explore and expand our knowledge on the utility of salivary 
biomarkers for detection of oral- and systemic diseases.  
The specific aims of this thesis were: 
 
 To explore salivary biomarkers for periodontal disease as a complement to clinical 
examinations in epidemiological surveys. (Study I) 
 
 To explore salivary biomarkers for systemic diseases, to complement clinical examinations in 
epidemiological surveys. (Study II) 
 
 To investigate whether salivary concentrations of selected cardiovascular biomarkers could be 
used to identify patients with a previous MII and if such markers in plasma and saliva were 
related to periodontal status. (Study III) 
 
 To explore the levels of the inflammatory markers; MMP-8, -9, TIMP-1 and MPO in saliva, 
and their relationship to previous MI and periodontal disease. (Study IV) 
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MATERIALS AND METHODS 
 
This thesis utilizes of two different projects: Skåne cohort and PAROKRANK sub-cohort.  
 
 
SKÅNE COHORT – STUDY POPULATION (STUDIES I & II) 
 
A randomly selected sample of 1000 adults living in Skåne, a county in the southern part of Sweden, 
was invited to participate in a clinical study of oral health. The individuals were 20–89 years old and 
were registered living in Skåne during 2007. The participant list was obtained from The Swedish 
Government’s Person Address Register and included background variables, such as gender, domicile, 
address and age in 5-year-intervals. Of the original sample, 11 individuals had moved from the region, 
14 had an unknown address and nine were deceased, thus leaving 966 individuals as the initial 
sample. In total, 451 individuals were examined clinically 232 (51%) women and 219 (49%) men. 
The clinical examinations were performed between March 2007 and November 2008 and took place 
at the Faculty of Odontology at Malmö University, Sweden, and at three clinics of the Public Dental 
Service in Helsingborg, Kristianstad and Ystad, in Skåne. Dentists were coordinated regarding 
diagnostic criteria through comprehensive written instructions, practice and through discussing 
clinical cases.  
 
 
Questionnaire 
 
All the clinically examined participants were asked to respond to a questionnaire, and only one 
failed to answer. This consisted of 58 questions concerning patient perception of oral health, oral 
healthcare needs, pain, use of oral healthcare, dental materials and background factors (82). Further, 
anamnestic data including diseases, use of medication, smoking and snuffing habits were collected. 
Patients who were not able to or were not interested in being clinically examined were contacted by 
the phone to be part of a non-response analysis, and 175 of these individuals answered the same 
questionnaire as the individuals participating in the clinical study. Individuals who filled in the 
questionnaire as a non-response analysis were more likely to be born in Sweden, have a lower 
educational level and were missing a higher number of teeth than those participating in the clinical 
study. These differences can most likely be explained by the fact that the non-response group 
included most of the oldest individuals compared with the clinical study. The individuals, who 
neither participated in the clinical examination nor answered the questionnaire, were those who 
could not be reached by the phone or letter, were unable to take part due to bad health, due to old 
age or were simply not interested in participating in this study.  
 
 
Clinical examination 
 
The clinical examinations were performed by dentists, and 90.5% of the examinations were 
performed by four of  those dentists, all employed at the Department of Oral Diagnostics, Faculty of 
Odontology, Malmö University. All patients were examined using typical examination procedures in 
standard surgeries.  All clinical periodontal measurements were recorded at four sites (buccal mesial, 
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lingual and distal) on each tooth. Presence of visible plaque was recorded after drying with air. 
Probing pocket depth (PPD) was measured parallel to the tooth with a periodontal probe with 1mm 
grading (Hu-Friedy PCPUNC157). The deepest pocket ≥ 4 mm was registered. Bleeding on probing 
(BOP) was recorded after probing of the pockets. Third molars, root remnants that could not be used 
for restorations and dental implants were excluded in all measurements. 
 
 
Radiographical examination 
 
Digital panoramic and four bitewing radiographs taken on all participants were subjected to thorough 
examination. As a result, eight individuals were excluded: two subjects were edentulous, one person 
was edentulous but with dental implants, radiographs were missing from four individuals, and finally 
for one individual the radiographs were of an unacceptable quality. Therefore, the final study sample 
comprised of 443 participants (45.8% of the initial sample). To calculate intra-observer agreement, 
the observer performed a new assessment of the marginal bone level in 100 individuals. The 
radiographs were randomly chosen by another person to represent an even distribution of patients who 
had been classified in one of the three different categories.  
The periodontal diagnosis was based on radiographic assessment only. Groups were defined as 
following:  
PD– = loss of supporting bone tissue < 1/3 of the root length  
PD = loss of supporting bone tissue > or = 1/3 of the root length in < 30% of the teeth  
PD+ = loss of supporting bone tissue > or = 1/3 the root length in > or = 30% of the teeth 
Subjects with no or minor bone loss, i.e. PD- constituted 69% of the population. Twenty percent of 
the study population had marginal bone loss corresponding to localized periodontal disease (PD) and 
11% exhibited generalized periodontal bone loss (PD+). 
 
Saliva sampling and sample preparation for analysis  
Sample collection: Stimulated saliva was collected over 5 minutes with chewing on 0.5g of paraffin 
into a graded test-tube. The collected amount was determined, excluding the foam. Saliva sampling 
and scoring of results was performed by trained dental assistants. Collected samples were 
immediately frozen at ‒20o C until processing. The present study includes 441 saliva samples from 
subjects with and without experience of periodontitis. 
Sample preparation: The samples were thawed and centrifuged at 500 g for 10 minutes at 4
o
C. The 
supernatants were collected and divided into several aliquots that were quick frozen and stored at ‒20o 
C until analysis. Each aliquot was used only once in an assay and then discarded. The pellets, 
containing whole cells, were resuspended in 200μL PBS and transferred to 1.5 mL Eppendorf tubes 
(Eppendorf, Hauppauge, NY, USA), immediately frozen and stored at ‒80o C. 
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PAROKRANK PROJECT (PERIODONTAL DISEASE AND THE RELATION 
TO MYOCARDIAL INFARCTION STUDY) - STUDY DESIGN (STUDIES III & 
IV) 
 
PAROKRANK is as a multicentre, prospective, case-control study that was initiated and conducted 
by a group of Researchers from the Departments of Medicine and Odontology at the Karolinska 
Institutet, Stockholm. 805 patients with MI and 805 randomly selected and matched controls were 
included. After initial examinations the participants were followed for two years [Figure 7]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients 
In a sub cohort, saliva-based studies of PAROKRANK, a total number of 200 patients with previous 
AMI and 200 healthy controls (non-AMI) were recruited. Patients were consecutively enrolled 
between May 2010 and December 2011 from coronary care units at 11 hospitals around Sweden. 
Inclusion criteria included below 75 years with a first MI. Patients were introduced to the National 
Quality Registry for Suspect Acute Coronary Syndromes (RIKS-HIA). The registry for Secondary 
Prevention Following Coronary Intensive Care (SEPHIA), was used for follow-up eight to ten weeks 
after the index event. In addition, the data were collected via a web based case report form (CRF) 
developed specifically for this purpose. Selected data from this database was used in the present 
subgroup analyses. 
 
 
Figure 7: A schematic presentation of the PAROKRANK original study plan 
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Controls 
Control subjects were randomly collected from the National Population Registry and were matched 
for age, gender and postal code. Exclusion criteria consisted of previous MI, cardiac valvular affected 
heart disease, and language barriers. Contact was established via phone by a study nurse at the 
coordinating centre (Karolinska University Hospital) providing information on the PAROKRANK 
project. Consenting persons underwent a structured interview on general health and were referred to a 
local centre for an extensive health and dental examination within one to two weeks of recruitment of 
the respective MI patient according to the principles outlined above for patients.  
 
 
Examinations 
 
Follow-up visit at Cardiology and Dental Departments  
All patients and controls attended the local cardiology departments for laboratory measurements and 
questionnaire evaluation, and to the local dental department for extensive periodontal evaluation and 
salivary collection. Patients were examined eight to ten weeks after the MI and matched controls were 
examined within one to two weeks after the patients. All participants fasted and refrained from 
smoking for 12 hours prior to sampling. Morning medications were taken as usual with a small glass 
of water. Venous blood samples were collected in EDTA-coated tubes. The investigators performing 
the dental examinations were coordinated regarding examination procedure and diagnostic criteria 
through comprehensive written instructions.  
 
 
 
Questionnaire 
 
All participants in this investigation were asked to respond to a validated questionnaire, comprising of 
various questions related to family history, previous diseases in particular inflammatory disorders, 
diet, weight/waist circumference, glucometabolic perturbations, smoking, pulmonary diseases, 
socioeconomic factors, stress at work and home, depression and exhaustive syndromes, and 
information about general oral health status. 
 
Dental examination 
A standardised dental examination, including panorama x-ray was performed at hospital discharge of 
week’s eight to ten for the MI patients. The controls were investigated at the same local center during 
the same period, within one to two weeks after the matched patients.  
Participants were examined clinically for number of present teeth, soft tissue pathologies, dental 
caries and periodontal status, including probing pocket depth of four sites per tooth, bleeding on 
probing and plaque score as present or absent, mobility and furcation involvement were recorded. The 
periodontal status of all participants was classified according to clinical criteria, such as number of 
pathological pockets ≥ 4 mm and gingival inflammation. 
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No data based on radiographic evaluations relating to alveolar bone level was available at the time of 
present subgroup analyses. 
Clinical periodontal diagnosis was based on:  
Gingivitis: bleeding on probing without loss of connective tissue attachment 
Localized periodontitis:  30% of the teeth are affected 
Generalized periodontitis: >30% of the teeth are involved 
The severity of the disease was divided into three sub categories based to the amount of clinical 
attachment loss: Slight: 1‒2 mm; Moderate: 3‒4 mm; Severe:  ≥ 5 mm 
 
Assessment of AMI 
The AMI was diagnosed by the physician in charge according to international definition of MI, 
(83,84) including the detection of a rise and/or fall of cardiac biomarkers, with at least one of the 
values being elevated (> 99th percentile upper reference limit), together with either typical symptoms/ 
ECG changes/ myocardial loss on imaging methods or thrombus on coronary angiography. 
 
Saliva sampling and sample preparation for analysis  
Sample collection: Stimulated saliva samples were obtained from all individuals in the sub cohort 
(200 cases and 200 controls) by chewing paraffin wax up to 10 minutes. The produced saliva was 
collected into a graded test-tube. The saliva collection continued until 2 mL of saliva was obtained or 
until 10 minutes had passed and the volume provided recorded if 2 mL was not obtained. The 
collected amount was determined, excluding the foam. Collected samples were immediately frozen at 
–20°C until processing.  
Sample preparation: After completing the saliva sampling, each vial of saliva was centrifuged at 500g 
for 5 minutes, at 5°C, the supernatants were aliquoted into 1.5mL Eppendorf tubes (Eppendorf, 
Hauppauge, NY, USA), and stored at ‒80°C. Each saliva aliquot was used twice for the determination 
of selected biomarkers. 
 
Plasma samples  
Collected plasma samples were immediately frozen locally at –80 °C until transport to the central 
Bio-bank at Karolinska Institutet. EDTA plasma was used for determination of GDF-15, NT-proBNP 
and cystatin C concentrations.  Plasma analyses included 60 samples in total from the study subjects. 
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BIOCHEMICAL ANALYSES 
 
We have used different methods to analyze the biomarkers in saliva (Studies I, II, III & IV) and 
plasma (Study III). All the biochemical assays are described below.  
In Studies I & II, the analyzed biomarkers were detected in more than 99% of the samples, except for 
TNF-α where the concentration was below the detection level in more than 50% of the samples. 
In Study III, we opted to use a routine method of analysis of Tn I in blood but we were unable to 
detect Tn I levels in stimulated saliva samples.  
 
ARCHITECT i4000SR SYSTEM (Abbott) (Study III) 
 
The ARCHITECT i4000SR SYSTEM (Abbott) assay is a chemiluminescent microparticle 
immunoassay used as a routine method for the quantitative determination of cardiac Tn I in human 
biological fluids. This assay was used in Study III according to the instructions of the manufacturer to 
determine salivary levels of Tn I.  
 
In Study III, 25 (cases only- a pilot work) samples of saliva were analysed to determine Tn I levels. 
 
 
Bradford assay (Study I) 
 
The Bradford protein assay is a spectroscopic analytical procedure used to measure the concentration 
of protein in a solution. This assay was used in Study I according to the instructions of the 
manufacturer to determine the total protein concentration of the analyzed salivary biomarkers.  
 
In Study I, 441 samples of saliva were analysed to determine total protein concentration.  
 
Enzyme-linked immunosorbent assay (ELISA) (Studies I-IV) 
 
ELISA is a test that uses antibodies and color change to identify a substance. ELISA is a popular 
biochemistry assay that uses a solid-phase enzyme to detect the presence of a substance, usually an 
antigen, in a liquid or wet sample. TIMP-1 in Studies I & II was measured by ELISA kits (Amersham 
Biotrak, GE Healthcare, Buckinghamshire, UK) and in Study IV, MMP-9 and TIMP-1 levels were 
determined by ELISA kits (Immundiagnostik, Bensheim, Germany) according to the manufacturer’s 
instructions. Lysozyme levels in Studies I &II, and salivary and plasma levels of cystatin C and GDF-
15 in Study III were analyzed by ELISA (R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer’s instructions (85).  
 
In Studies I & II, 441 samples of saliva were analyzed to determine MMP-9, TIMP-1 and lysozyme 
levels.  
In Study III, 400 (200 cases & 200 controls) samples of saliva were analyzed to determine cystatin C 
and GDF-15 levels. 
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In Study III, 60 (30 cases & 30 controls) samples of plasma were analysed to determine cystatin C and 
GDF-15 levels. 
 
In Study IV, 400 (200 cases & 200 controls) samples of saliva were analyzed to determine MMP-9 
and TIMP-1 levels.  
 
 
Immulite 2000 XPi (Siemens, Diagnostic Product Corporation) (Study III) 
 
Immulite 2000 XPi a routine method used for the quantitative measurement of NT-proBNP in 
heparinized plasma, as an aid in the diagnosis of individuals suspected of having congestive heart 
failure. The test is further indicated for the risk stratification of patients with acute coronary syndrome 
and congestive heart failure. The Immunlite 2000 XPi method was used in Study III to analyze the 
concentrations of NT-proBNP in plasma and saliva according to the manufacturer’s instructions. 
 
In Study III, 60 (30 cases & 30 controls) samples of saliva were analyzed to determine NT-proBNP 
levels. 
 
In Study III, 60 (30 cases & 30 controls) samples of plasma were analyzed to determine NT-proBNP 
levels. 
 
Luminex assay (Studies I & II) 
 
Luminex is a multiplex assay that simultaneously measures multiple analytes in a single run/cycle in a 
single sample volume of the assay. This assay is used for detection and quantification of proteins and 
peptides, or nucleic acids in biological fluids. In Studies I & II, Luminex assay (BioRAD, Hercules, 
CA, USA) was used according to the manufacturer’s instructions to analyzed TNF-α, IL-1β, IL-6 and 
IL-8 concentrations in saliva.  
 
In Studies I & II, 441 samples of saliva were analyzed to determine TNF-α, IL-1β, -6 and -8 levels.   
 
Time-resolved Immunofluorometric assay (IFMA) (Studies I, II & IV) 
 
Time-resolved immunofluorometric assay (IFMA) is based on labeling immunoreactants with 
fluorescent probes. In Studies I, II & IV, MMP-8 concentrations in saliva were determined by IFMA 
according to the manufacturer’s instructions. The monoclonal MMP-8–specific antibodies (8708 and 
8706) were used as capture and tracer antibodies, respectively (86, 87). The tracer antibody was 
labeled using europium-chelate. The assay buffer contained 20 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 1 
mM CaCl2, 50 µM ZnCl2, 0.5 % bovine serum albumin, 0.05 % sodium azide, and 20 mg/L 
diethylenetriaminepentaacetic acid. Samples were diluted in assay buffer and incubated for one hour, 
followed by incubation for one hour with tracer antibody. Enhancement solution was added, and after 
five minutes fluorescence was measured using a fluorometer.   
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In Studies I & II, 441 samples of saliva were analyzed to determine MMP-8 levels.   
 
In Study IV, 400 (200 cases & 200 controls) samples of saliva were analyzed to determine MMP-8 
levels.  
 
Western Blot (Study IV) 
 
Western blot or immunoblot is used to detect specific proteins, where antibodies are used to detect 
proteins in the sample. In Study IV, the presence and molecular forms of MMP-8 in saliva samples 
were analyzed using Western blotting according to the manufacturer’s instructions (86, 88). Samples 
were boiled in non-reducing Laemmli’s buffer, proteins were separated by a gel-electrophoresis, the 
proteins were semi-dry transferred to nitrocellulose membranes and incubated in 5 % milk powder. 
The membranes were first incubated with specific primary antibodies at room temperature overnight 
followed by incubation with secondary antibodies conjugated to horseradish peroxidase. The proteins 
were detected by incubation with an enhanced chemiluminesence technique and quantified with a 
Bio-Rad Model GS-700 imagining Densitometer using the Analyst 
TM
 program with correction for 
background values (86, 88). 
 
In Study IV, 400 (200 cases & 200 controls) samples of saliva were analyzed to determine MMP-8 
levels.  
 
 
STATISTICAL ANALYSES  
 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version 18 or 
22 (SPSS Inc., Chicago, IL). Differences were considered significant at a probability level of p < 0.05.  
In Study I, parametric tests were applied to calculate the characteristics and clinical variables 
between the groups. One-Way ANOVA and General Linear Model were used to compare 
biomarkers between the groups of periodontal health. The influence of smoking on salivary 
biomarkers was analyzed using a One-Way ANOVA test. A Tukey HSD Post-Hoc test was 
performed to calculate multiple comparisons between and within the groups of participants with and 
without experience of periodontitis.  
In Study II, demographics of the study population was calculated by parametric tests. The 
significances of the differences in biomarker concentration between smoker/non-smoker, men/women 
and between those suffering with or without the indicated disease were calculated with Independent 
samples t-test. These data are expressed as mean ± standard deviation (SD). Significance of the 
differences, after compensation for age group, gender and smoking, was performed using the General 
Linear Model. The correlation between age and biomarker concentration was calculated with Pearson 
Product Moment Correlation test. 
In Study III, parametric tests were applied to calculate the characteristics and clinical variables 
between the groups.  Independent samples t-test was used for comparing mean values of the analyzed 
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biomarkers to determine the association of cardiac markers and systemic conditions. These data are 
expressed as mean ± SD. The correlation between periodontal status and biomarkers were calculated 
using Pearson- and Spearman’s correlation tests. Values under the detection limit were not included 
into the statistical analysis. 
In Study IV, parametric tests were applied to calculate the characteristics and clinical variables 
between the groups.  Independent samples t-test and General Linear Model were used to compare 
biomarkers between the groups were used to compare mean values of the analyzed biomarkers. 
These data are expressed as mean ± SD. The correlations were calculated by using Pearson- and 
Spearman’s correlation tests.  
 
ETHICAL CONSIDERATIONS  
 
Both projects conformed to good clinical practice guidelines and followed the recommendations of 
the Helsinki Declaration. All participants gave their written informed consent to the study protocols. 
The statistical analyzes were performed so that all participants were unidentifiable. Local Ethical 
Review Boards approved the protocol of the Skåne cohort and PAROKRANK project respectively.  
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MAIN RESULTS 
 
SKÅNE COHORT 
 
Baseline characteristics in Skåne population (Studies I and II) 
 
The characteristics of the study population are presented in Table 2. There was a significant difference 
between men and women in regard to mental disorders and periodontal parameters, such as plaque 
and gingival indices, and PPD 4‒5mm. The mean age, plaque- and gingival indices, PPD 4‒5mm and 
> 5mm, the percentage of smokers, patients reporting heart disease, previously undergoing heart 
surgery, hypertension and bowel disease were higher amongst the male subjects.  
 
 
Table 2: Demography of the study population in studies I and II 
Variable Female  
n = 230 
Male  
n = 218 
p 
Age (Mean ± SD) 47.9 ± 17.1 49.3 ± 16.9 0.39 
Smoking (%) 16.1 17.8 0.63 
No. of remaining teeth (Mean ± SD) 25.7 ± 3.6 25.1 ± 5.1 0.14 
Plaque Index (Mean ± SD) 17.7 ± 19.7 26.8 ± 23.5 0.001 
Gingival Index (Mean ± SD) 26.3 ± 19.8 30.9 ± 21.5 0.01 
Probing Pocket depth 4–5mm  (Mean ± SD) 6.1 ± 7.8 7.8 ± 9.9 0.04 
Probing Pocket depth  >5mm (Mean ± SD) 0.6 ± 1.8 0.7 ± 2.4 0.55 
Heart surgery (%)  1.3 3.7 0.11 
Heart disease (%) 7.5 8.4 0.74 
Hypertension (%) 14.2 20.5 0.08 
Diabetes (%) 3.9 3.2 0.68 
Bowel disease (%) 6.6 7.4 0.74 
Muscle and joint diseases (%) 25.7 20.5 0.19 
Tumor (%) 4.0 3.3 0.68 
Mental disorders (%) 8.8 2.8 0.007 
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Study I 
 
Table 3 demonstrates the demographic data related to periodontally healthy and affected subjects of 
the study population (n = 441). There was a significant difference between the groups with regards to 
all variables, except smoking and gingival index. The mean plaque and gingival indices, PPD 4–5mm 
and > 5mm, a reduction in the number of teeth and percentage of smokers were higher in the severe 
periodontitis group (PD+) compared with the other two groups. Participants reporting with 
hypertension, bowel diseases, tumors, diabetes, muscle and joint diseases were higher amongst the 
PD‒ subjects.  
 
Table 3: Demographic data based on periodontally healthy and affected subjects in the study 
population 
Periodontal diagnosis/ 
Variable 
PD-  
n = 303 
PD  
n = 89 
PD+  
n = 49 
p 
Age (Mean ± SD) 42.6 ± 15.5 59.9 ± 11.4 64.4 ± 11.8 0.001 
No. of remaining teeth (Mean ± SD) 26.4 ± 3.53 25.0 ± 3.27 22.0 ± 4.82 0.001 
Plaque Index (Mean ± SD) 19.8 ± 18.6 23.1 ± 23.7 35.5 ± 31.1 0.001 
Gingival Index (Mean ± SD) 28.1±19.7 27.8 ± 19.1 34.8 ± 27.2 0.41 
Probing Pocket depth 4–5 mm (Mean ± SD) 5.23 ± 7.32 8.51 ± 8.26 16.9 ± 13.9 0.001 
Probing Pocket depth >5 mm (Mean ± SD) 0.19 ± 0.59 0.58 ± 1.46 4.31 ± 5.54 0.001 
Heart surgery (n/ %) 2/ 0.7 4/ 4.5 5/ 10.2 0.001 
Heart disease (n/ %) 11/ 3.6 12/ 13.5 12/ 24.5 0.001 
Hypertension (n/ %) 33/ 10.9 26/ 29.2 17/ 34.7 0.001 
Diabetes (n/ %) 6/ 2.0 5/ 5.6 5/ 10.2 0.01 
Bowel diseases (n/ %) 17/ 5.6 6/ 6.7 8/ 16.3 0.05 
Muscle and joint diseases (n/ %) 53/ 17.5 31/ 34.8 18/ 36.7 0.001 
Tumor (n/ %) 7/ 2.3 3/ 3.4 6/ 12.2 0.01 
Smoking (%) 16.2 13.5 28.6 0.06 
 
In addition, all the analyzed biomarkers: IL-1β, -6 and -8, MMP-8, TIMP-1, lysozyme, MMP-
8/TIMP-1 ratio and the total protein concentration from the three different patients groups were 
observed. The mean concentrations of IL-1β, MMP-8 and MMP-8/TIMP-1 ratio showed significant 
differences between the groups, and significance level remained after adjustment for gender, age and 
smoking. Additionally, multiple comparisons between and within the groups of participants with and 
without periodontitis with regards to IL-1β, MMP-8 and MMP-8/TIMP-1 ratio was studied, and the 
Tukey HSD Post-Hoc test showed significant differences between the PD- group and the PD+ group 
with severe periodontal disease.  
The influence of tobacco smoking on the analyzed salivary biomarkers and the concentration of total 
protein were also studied. The results revealed that when the subjects were compared according to 
their smoking habits, significantly lower levels of IL-8, MMP-8/TIMP-1 ratio, and the total protein 
concentration were found in smokers. Smokers compared with non-smokers showed slightly lower 
concentrations of salivary MMP-8 (p = 0.052).  
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The figure shows the percentage of three patient groups based on the periodontal diagnosis [Figure 8]. 
 
 
 
 
 
 
 
 
 
The correlation and significant levels between the clinical variables and analyzed biomarkers is 
demonstrated in Table 4. The most pronounced correlation was found between IL-1β and the number 
of deep pockets (>5 mm). TIMP-1 showed a negative correlation with BOP and the number of deep 
pockets (>5 mm). A number of analyzed biomarkers demonstrated a weak but statically significant 
correlation with the clinical variables.   
 
Table 4: The correlation (R) and p-values between the clinical variables and analyzed 
biomarkers 
Biomarker/ 
Clinical parameter 
IL-1β 
 
R 
(p) 
IL-8 
 
R 
(p) 
MMP-8 
 
R 
(p) 
TIMP-1 
 
R 
(p) 
MMP-8/ 
TIMP-1 
R 
(p) 
Total 
protein 
R 
(p) 
Visual plaque index  0.3 
(0.001) 
0.1 
(0.01) 
0.1 
(0.01) 
-0.1 
(0.05) 
0.2 
(=0.001) 
0.1 
(0.01) 
Bleeding on probing 
index 
0.3 
(0.001) 
0.1 
(0.01) 
0.2 
(0.001) 
-0.1 
(0.01) 
0.2 
(0.001) 
0.2 
(=0.01) 
Probing Pocket depth  
 4–5 mm 
0.3 
(0.001) 
0.1 
(=0.001) 
0.2 
(0.001) 
-0.0 
(0.296) 
0.3 
(0.001) 
0.2 
(0.001) 
Probing Pocket depth  
>5 mm 
0.4 
(0.001) 
0.1 
(0.01) 
0.1 
(0.01) 
-0.1 
(0.01) 
0.2 
(0.001) 
0.2 
(0.001) 
 
Study II 
 
The influence of gender, smoking and age on the concentration of analyzed salivary IL-1β, -6, -8, 
lysozyme, MMP-8, TIMP-1 and total protein concentration presented in Table 5. Mean salivary levels 
were higher in male subjects compared to female subjects but only IL-1β and -8 reached a significant 
level. Non-smokers compared to smokers had significantly elevated levels of IL-8, MMP-8, ratio of 
MMP-8/TIMP-1 and total protein concentration. All the analyzed biomarkers, except IL-6 and TIMP-
1, correlated significantly with variable age. 
Figure 8: Percentage of three patient groups based on the 
periodontal diagnosis 
Patient Groups 
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Table 5: The influence of gender, smoking, and age on analyzed salivary biomarkers and total protein 
concentration 
Biomarker Gender p Smoking p Correlation 
with age 
 Female Male  Yes No  R p 
 n = 226 n = 215  n = 75 n = 366    
 Mean ± SD Mean ± SD  Mean ± SD Mean ± SD    
IL-1β (pg/mL) 62.7 ± 117 87.2 ± 115 0.03 52.2 ± 74.8 79.3 ± 123 0.07 0.1 0.003 
IL-6 (pg/mL) 7.5 ± 8.9 8.4 ± 13.6 0.34 7.1 ± 7.9 8.1 ± 12.0 0.47 0.03 0.24 
IL-8 (pg/mL) 412 ± 446 601 ± 899 0.005 342 ± 351 537 ± 758 0.03 0.2 0.001 
Lysozyme (ng/mL) 362 ± 360 431 ± 485 0.09 416 ± 486 392 ± 413 0.65 -0.2 0.001 
MMP-8 (ng/mL) 287 ± 235 301 ± 296 0.59 239 ± 233 305 ± 271 0.05 0.2 0.001 
TIMP-1 (ng/mL) 253 ± 193 274 ± 195 0.27 288 ± 242 259 ± 189 0.24 -0.0 0.48 
MMP-8/ TIMP-1  0.58 ± 0.76 0.56 ± 0.95 0.89 0.35 ± 0.34 0.60 ± 0.92 0.02 0.2 0.001 
Total protein 
(ug/mL) 
833 ± 448 809 ± 406 0.55 730 ± 403 840 ± 431 0.04 0.1 0.008 
 
Table 6: Illustrates the mean salivary concentrations related to different systemic diseases/ conditions 
of the study population. Patients reporting hypertension presented with higher concentrations of 
MMP-8 and lysozyme, as well as an increased MMP-8/TIMP-1 ratio but these differences were lost 
after adjustment for age group, gender and smoking habits. Diabetes patients had elevated 
concentrations of MMP-8 and a higher MMP-8/TIMP-1 ratio. These differences were more 
pronounced after compensation for age group, gender and smoking. Muscle and joint diseases were 
associated with increased levels of IL-1β, MMP-8 and the ratio MMP-8/TIMP-1.  Furthermore, 
patients who responded that they were or had been suffering from any type of tumor had more than 
twice the concentration of IL-8 compared to those who had not had tumors. This difference was 
significant and remained after adjustment for age group, gender and smoking habits. Bowel disease 
was associated with elevated concentrations of IL-8 and total protein concentration. The patients that 
had previously undergone heart surgery had higher concentrations of MMP-8, and this difference 
remained after compensation for age group, gender and smoking. Variable inflammation, which 
included a combination of systemic conditions, such as heart disease, hypertension, bowel diseases, 
and muscle and joint diseases, was associated with increased levels of IL-8, MMP-8, the ratio of 
MMP-8/TIMP-1, lysozyme and total protein concentration.  
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Table 6: Mean salivary concentrations related to systemic diseases/ conditions 
Condition/ 
Biomarker 
Diabetes  
Mean ± SD 
Yes:16 
  No: 425 
p1 p2 Hypertension  
Mean ± SD 
Yes: 76 
 No: 365 
p1 p2 Muscle/joint 
diseases  
Mean ± SD 
Yes:102 
 No: 339 
p1 p2 
IL-1β  
(pg/mL) 
65.0 ± 80.6 
75.0 ± 118 
0.6 0.4 94.5 ± 166 
71 ± 103 0.1 0.9 
101 ± 154 
66.7 ± 102 
0.008 0.02 
MMP-8  
(ng/mL) 
481 ± 402 
287 ± 258 
0.08 0.02 371 ± 386 
278 ± 231 
0.006 0.41 356 ± 331 
275 ± 241 
0.007 0.04 
MMP-
8/TIMP-1  
1.76 ± 2.45 
0.52 ± 0.70 
0.06 0.001 0.78 ± 1.16 
0.51 ± 0.77 
0.01 0.8 0.77 ± 1.40 
0.50 ± 0.59 
0.005 0.05 
Lysozyme 
(ng/mL) 
338 ± 172 
398 ± 433 
0.2 0.7 
307 ± 325 
414 ± 442 
0.05 0.6 337 ± 265 
414 ± 463 
0.1 0.9 
T.P.C (ug/mL) 867 ± 235 
820 ± 434 
0.5 0.9 877 ± 482 
810 ± 416 
0.2 0.9 
901 ± 491 
798 ± 406 
0.03 0.1 
p1 indicates significance of the differences after a bivariate comparison;  p2 indicates the significance after compensation for differences 
in gender, age group and smoking habits. 
T.P.C = Total protein concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
 
PAROKRANK SUB-COHORT 
 
Baseline characteristics in the sub-cohort of PAROKRANK participants (Studies III and IV). Clinical 
characteristics and background variables of the study subjects are presented in Table 7. The number of 
smokers was significantly higher in the non-MI group. In MI patients, the mean value of dental caries 
was significantly higher compared to the non-MI subjects. The number of cases reporting 
hypertension, diabetes, respiratory disease, joint disease, showed all clinical periodontal parameters, 
and moderate and severe periodontitis patients were higher in the MI group. In non-MI subjects, the 
number of patients with gingivitis, mild periodontitis, kidney disease, cancer and bowel disease were 
higher in comparison to MI patients but it did not reach a significant level.   
 
Table 7: Demography of the study population in Studies III and IV 
 
Condition/ 
Variable 
MI  
n = 200 
non-MI  
n = 200 
p 
Age (Mean ± SD) 61.5 ± 7.99 61.7 ± 7.96 0.93 
Gender (M) (n) 169/ 50.1 168/ 49.9 0.89 
Smoking    
Yes 27/ 13.5 46/ 23  
No 60/ 30.0 68/ 34.0 0.03 
Ex-smoker 113/ 56.5 86/ 43.0  
Snuffing    
Yes  9/ 4.5 24/ 12.0 0.06 
 No  164/ 82.0 150/ 75.0  
 Ex-snuffer  26/ 13.0 25/ 12.5  
Dental caries (Mean ± SD) 0.43 ± 1.20 0.24 ± 0.60 0.001 
Dental plaque (Mean ± SD) 52.1 ± 30.7 49.3 ± 28.9 0.26 
BOP (Mean ± SD) 32.7 ± 25.5 28.4 ± 24.3 0.23 
PPD 4–5 mm (Mean ± SD) 14.3 ± 13.6 13.0 ± 14.9 0.91 
PPD ≥ 6 mm (Mean ± SD)  1.96 ± 4.93 1.51 ± 4.58 0.30 
Total PPD mm (Mean ± SD) 68.9 ± 75.7 57.1 ± 71.5 0.16 
Clinical periodontal diagnosis     
Healthy (n/ %) 45/ 22.5 54/ 27.0  
Gingivitis (n/ %) 64/ 32.0 70/ 35.0  
Mild periodontitis (n/ %) 55/ 27.5 57/ 28.5 0.17 
Moderate periodontitis (n/ %) 20/ 10.0 10/ 5.0  
Severe periodontitis (n/ %) 16/ 8.0 9/ 4.5  
Hypertension (n/ %) 75/ 42.6 67/ 33.5 0.18 
Diabetes (n/ %) 15/ 8.5 10/ 5.0 0.26 
Respiratory disease (n/ %) 22/ 11.4 18/ 6.1 0.33 
Joint disease (n/ %) 29/ 15.1 21/ 10.6 0.22 
Kidney disease (n/ %) 10/ 5.1 12/ 6.0 0.92 
Cancer (n/ %) 11/  5.6 13/ 6.6 0.89 
Oral Cancer (n/ %) 2/ 1.0 2/ 1.0 0.93 
Bowel disease (n/ %) 3/ 1.5 5/ 2.5 0.60 
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Study III 
 
Plasma and salivary cardiac related markers are presented in Table 8. Salivary levels of cystatin C 
were significantly lower in MI patients. Apart from cystatin C no other analyzed salivary biomarkers 
differed between the MI and control group. Correlation analyses were performed to investigate the 
correlation between plasma and salivary cardiac related markers but there was no correlation between 
analyzed markers in saliva and plasma. The levels of NT-proBNP and GDF-15 were significantly 
higher in plasma of MI patients than control subjects.  
 
Table 8: Mean concentrations and the correlation of biomarkers in plasma and 
stimulated saliva  
Condition/ 
Biomarker 
MI 
Mean ± SD (n) 
non-MI 
Mean ± SD (n) 
p R 
Cystatin C 
   Plasma (ng/L) 
   Saliva (ng/L) 
 
922 ±178 (30) 
694 ± 331 (200) 
 
912 ± 192 (30) 
715 ± 366 (200) 
 
0.83 
0.05 
0.1 
NT-proBNP 
   Plasma (ng/L)   
   Saliva (ng/L)    
 
310 ± 471 (30) 
11.3 ± 12.5 (30) 
 
29.4 ± 48.2 (30) 
13.5 ± 13.6 (30) 
 
0.001 
0.48 
0.2 
GDF-15 
   Plasma (ng/L) 
   Saliva (ng/L) 
 
983 ± 613 (30) 
69.4 ± 84.9 (200) 
 
625 ± 280 (30) 
 76.2 ± 105 (200) 
 
0.005 
0.48 
0.2 
 
 
Table 9 shows the correlation between periodontal status and the analyzed biomarkers in MI patients 
and non-MI subjects. A negative correlation was found in the presence of dental plaque and salivary 
cystatin C levels in MI patients.  The variables: BOP, PPD 4–5 mm and ≥ 6 mm and the clinical 
periodontal diagnosis were significantly correlated with GDF-15 levels in saliva in both groups. In 
non-MI subjects, significant negative correlation with cystatin C levels in saliva was found in 
presence of plaque and BOP. Further, the clinical periodontal diagnosis correlated negatively with 
salivary NT-proBNP levels in the same group.    
     
      
Table 9: The correlation between periodontal status and the salivary cardiac markers 
Salivary biomarker/ 
Clinical variable 
Cystatin C (R/p) 
MI             non-MI 
NT-proBNP (R/p) 
MI             non-MI 
GDF-15 (R/p) 
MI             non-MI 
Plaque -0.2/ 0.02 -0.3/ 0.001 0.1/ 0.39 0.2/ 0.32 0.0/ 0.94 0.1/ 0.25 
BOP -0.1/ 0.46 -0.2/ 0.006 0.0/ 0.81 -0.2/ 0.34 0.1/ 0.01 0.2/ 0.09 
PPD 4–5mm 0.0/ 0.89 -0.0/ 0.56 -0.1/ 0.74 -0.3/ 0.13 0.3/ 0.001 0.2/ 0.002 
PPP ≥ 6mm 0.0/ 0.82 -0.1/ 0.33 -0.0/ 0.86 -0.2/ 0.29 0.2/ 0.01 0.2/ 0.02 
Total amount of PPD (mm) 0.0/ 0.78 -0.1/ 0.16 -0.1/ 0.53 -0.3/ 0.13 0.1/ 0.09 0.2/ 0.007 
C.P.D 0.1/ 0.14 0.0/ 0.60 0.0/ 0.93 -0.4/ 0.01 0.3/ 0.001 0.2/ 0.004 
  C.P.D = Clinical Periodontal diagnosis 
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The association of the analyzed salivary biomarkers and systemic conditions in MI and non-MI subjects are 
presented in Table 10. Significantly higher levels of salivary cystatin C was found in MI patients with 
hypertension than non-MI subjects with same condition. Mean salivary cystatin C, GDF-15and NT-
proBNP levels were higher in MI patients with respiratory disease as compared to the controls but 
only cystatin C and NT-proBNP reached a significant level. In addition, salivary NT-proBNP levels 
were higher in MI patients who felt stressed at work in comparison to non-MI patients, although not 
statistically significant. The levels of cystatin C, GDF-15 and NT-proBNP in plasma were 
significantly higher in MI patients with respiratory disease, reported hypertension and who felt 
stressed at work than in controls. MI patients reporting with respiratory disease had significantly 
elevated levels of cystatin C in plasma than in control subjects. 
 
 
 
 
Study IV 
 
Mean salivary levels of MMP-8 and -9, MPO, TIMP-1 and the ratios of MMP-8 and -9/ TIMP-1 from 
MI and non-MI subjects is illustrated in Table 11. The results showed that salivary MMP-8, MPO and 
TIMP-1 levels were higher in non-MI subjects compared to patients with MI but only MMP-8 
reached a significant level and the difference was remained after adjustment for smoking, BOP, PPD 
4–5mm and ≥ 6mm. MPO levels were slightly significantly elevated in the non-MI group but the 
difference was clearer after compensation for smoking and periodontal parameters. MMP-9/ TIMP-1 
ratio were enhanced in MI patients relative to non-MI subjects. In addition, the different enzyme 
forms (pro- and active) of MMP-8 were observed by Western blot analyzes. The results revealed that 
Table 10: The association of the analyzed salivary biomarkers and systemic conditions in MI 
and non-MI subjects 
Biomarker/ 
Condition 
 
Saliva: 
Cystatin C 
Mean ± SD (n) 
p 
Saliva: 
NT-proBNP 
Mean ± SD (n) 
p 
Saliva: 
GDF-15 
Mean ± SD (n) 
p 
Hypertension 
 
 
 
 
 
 
Yes                      MI 
Non-MI 
784 ± 338 (75) 
671 ± 340 (67) 
0.05 
16 ± 12.8 (11) 
19.1 ± 19.5 (5) 
0.72 
69.1 ± 75.0 (75) 
92.2 ± 134 (67) 
0.20 
No                        MI 
Non-MI 
651 ± 300 (100) 
737 ± 378 (131) 
0.21 
15.6 ± 12.5 (14) 
13.2 ± 12.4 (24) 
0.53 
73.5 ± 96.1 (100) 
68.2 ± 86.1 (131) 
0.67 
Respiratory disease       
Yes                      MI 
Non-MI 
813 ± 379 (32) 
698 ± 347 (23) 
0.01 
6.8 ± 11.8 (3) 
0.00 ± 0.00 (2) 
0.04 
72.0 ± 74.7 (32) 
59.8 ± 79.1 (23) 
0.56 
No                       MI 
Non-MI 
661 ± 314 (161) 
717 ± 371 (175) 
0.13 
14.7 ± 12.5 (25) 
15.0 ± 13.6 (27) 
0.81 
70.4 ± 88.1 (161) 
78.7 ± 108 (175) 
0.44 
Stressed at work       
Yes                       MI 
  Non-MI 
663 ± 327 (121) 
668 ± 357 (122) 
0.91 
15.9 ± 12.4 (17) 
10.4 ± 11.9 (20 
0.17 
73.8 ± 89.5 (121) 
81.7 ± 126 (122) 
0.58 
No                        MI 
              Non-MI 
734 ± 317 (77) 
782 ± 368 (77) 
0.38 
11.6 ± 12.2 (12) 
22.1 ± 14.5 (9) 
0.09 
63.3 ± 78.2 (77) 
68.5 ± 58.1 (77) 
0.64 
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MMP-8, obtained as densitometric units from Western blot scanned images, did not differ between 
the study groups but there was a tendency for the active form MMP-8 to be somewhat higher in the 
non-MI group.  
 
 
Table 11: The mean levels of MMP-8, -9, MPO, TIMP-1 and the ratio of MMP-8 and 
-9/TIMP-1 in stimulated saliva from MI and non-MI subjects 
Condition/ 
Biomarker 
MI 
Mean ± SD 
non-MI 
Mean ± SD 
p1 
 
p2 
MMP-8 (ng/mL) 440 ± 377 543 ± 398 0.008 0.003 
MMP-9 (ng/mL) 260 ± 257 264 ± 217 0.88 0.78 
MPO (ng/mL) 1637 ± 1386 1899 ± 1447 0.06 0.02 
TIMP-1 (ng/mL) 208 ± 119 229 ± 129 0.08 0.09 
MMP-8/ TIMP-1 1.63 ± 2.79 1.62 ± 2.48 0.99 0.60 
MMP-9/ TIMP-1  0.74 ± 1.45 0.56 ± 0.81 0.12 0.20 
                       p1 indicates significance of the differences after a bivariate comparison 
                          p2 indicates the significance after compensation for differences in smoking, BOP, PPD 4–5 mm and PPD ≥ 6 mm. 
 
Table 12 illustrates correlations between periodontal status, gender and smoking with analyzed 
biomarkers and the ratios. The results showed a weak but significant positive correlation between 
most of the analyzed biomarkers and the registered clinical variables in both study groups. There was 
a negative correlation between TIMP-1 and clinical variables. Further, some of the biomarkers 
showed weak correlation with smoking. 
 
Table 12: The correlations of salivary MMP-8, -9, MPO, TIMP-1 and the ratios of MMP-8 and -
9/TIMP-1 measurements, and periodontal parameters, gender and smoking in MI and non-MI subjects. 
Clinical 
variable/ 
Biomarkers 
BOP 
 
MI        non-MI 
PPD 4–5 mm 
 
MI          non-MI 
PPD ≥ 6mm 
 
MI     non-MI 
C.P.D 
 
MI        non-MI 
Smoking 
 
MI       non-MI 
MMP-8 (ng/mL) 0.2** 0.4** 0.2* 0.2** 0.1 0.2** 0.2** 0.2** 0.0 0.0 
MMP-9 (ng/mL) 0.2** 0.0 0.1 0.0 0.2** 0.0 0.2* 0.0 0.0 0.2* 
MPO (ng/mL) 0.2** 0.3** 0.1 0.2* 0.2** 0.3** 0.2** 0.2** 0.0 -0.1 
TIMP-1 (ng/mL) -0.2* -0.2** 0.0 -0.1 -0.1 -0.1 -0.1 0.0 0.2* 0.2** 
MMP-8/ TIMP-1 0.3** 0.4** 0.2** 0.2* 0.4** 0.5** 0.3** 0.2* 0.0 -0.1 
MMP-9/ TIMP-1 0.3** 0.2** 0.1 0.0 0.4** 0.2** 0.2** 0.0 0.0 -0.2* 
   ** Correlation is significant at the 0.01 level; * Correlation is significant at the 0.05 level   
   C.P.D = Clinical Periodontal diagnosis 
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DISCUSSION 
 
 
Salivary diagnostics is an emerging research field. To use saliva as a diagnostic medium for 
biomarker detection for local and systemic diseases is of high scientific interest both in dental and 
medical professionals. A literature search of PubMed using the following search terms: “saliva and 
biomarkers” presented nearly 2000 publications over the past10 years, [Figure 9].  
 
 
 
 
 
 
 
 
 
 
 
 
Our findings related to the utilization of salivary biomarkers for the detection of oral and systemic 
diseases, in particular periodontal disease and MI. This may explore and improve current knowledge 
to provide a good platform for future studies.  
Human saliva has many biological functions, offering some distinct advantages for monitoring and 
detection of a number of diseases, such as periodontal disease, dental caries, oral cancer, breast 
cancer, and human immunodeficiency virus (41, 42, 89-91). Several types of inflammatory 
biomarkers (IL-1β, -6 and -8, TNF-α, MMP-8 and -9, MPO) associated with both oral and systemic 
diseases have been detected in saliva using different analyzing methods (1, 63, 64, 92, 93). The 
composition of salivary proteins differs in stimulated and unstimulated whole saliva. Thus, it is 
suggested to use unstimulated saliva to analyze salivary proteins as the outcome affects the saliva 
collection method (94, 95).  
In the study population of Skåne cohort, we investigated the possibility of using salivary biomarkers 
for oral (Study I) and systemic diseases (Study II) as a complement to clinical examinations. In Study 
I, IL-1β, MMP-8 and the ratio of MMP-8/TIMP-1 were found to be significantly enhanced in the 
saliva from subjects with severe periodontitis, suggesting that these components could be potential 
biomarkers for periodontitis/ local inflammation. Our findings regarding elevated salivary IL-1β and 
MMP-8 levels in periodontitis patients are in line with several previous studies (63, 96). IL-1β is an 
inflammatory biomarker and it remains to evaluate if it is possible to differentiate between gingivitis 
and periodontitis. Some studies have shown higher levels of IL-1β in GCF samples in sites with 
Figure 9: Publications based on salivary diagnostics from 2003-2012 
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periodontitis compared with GCF samples from gingivitis sites (97). One of the key biomarkers in 
inflammation process is MMP-8. Increased levels of MMP-8 in oral fluids are related to severity of 
periodontitis and it´s progression (98). Furthermore, chair-side tests measuring MMP-8 in mouth 
rinses have been shown to discriminate between gingivitis and periodontitis (99). Elevated levels of 
IL-1β and MMP-8 in GCF have also been associated with increased odds for subsequent attachment 
loss during periodontal maintenance (100). It is important to consider that analyses of GCF are site 
specific and saliva reflects the entire mouth. Furthermore, the salivary biomarkers analyzed in Study I 
were correlated significantly with most of the registered periodontal parameters. This could be an 
indication that the measured biomarkers reflect the degree of periodontal/ gingival inflammation 
rather than periodontal tissue destruction. The findings in Study I support the proposal that saliva 
could be used in epidemiological surveys to detect oral inflammations. 
Study II was performed to investigate selected salivary biomarkers (IL-1β, -6, -8, TNF-α, lysozyme, 
MMP-8 and TIMP-1) for detection of a few common systemic diseases. The results in this study 
showed that diabetes patients and patients who had undergone heart surgery had higher salivary 
MMP-8 levels. It is important to consider that patients who reported with previously undergone 
cardiac surgery and diabetes patients in this cohort were very few, eleven and sixteen respectively. 
Nevertheless, increased MMP-8 levels in association with diabetes have earlier been shown in saliva, 
GCF and in gingival tissues (98,101-104). The levels of IL-1β, IL-8 and MMP-8, as well as the 
MMP-8/TIMP-1 ratio were higher in subjects with muscle and joint diseases. Patients with bowel 
diseases had higher salivary levels of IL-8. Elevated salivary IL-8 levels in patients reported with 
experience of tumor diseases was found in our study, which is in line with a study performed by Wei 
and coauthors who investigated salivary IL-8 levels of patients with oral cancer (105). In addition, IL-
8 has been shown to be elevated in both serum and saliva in patients with head and neck squamous 
cell cancer (106). Salivary IL-8 appears to be good marker for evaluation of head and neck cancer, as 
well as in other clinical settings, such as muscle and joint diseases and inflammatory bowel disease.    
In Study III, the cardiac related biomarkers (cystatin C, GDF-15, NT-proBNP and Tn I) were chosen 
for their involvement in CVD. The diagnostic utility in saliva to differentiate between patients having 
had an AMI eight to ten weeks earlier, and non-AMI subjects were explored. Our results showed that 
salivary cystatin C levels were significantly lower in MI patients but cystatin C levels in plasma were 
higher in patients with MI. It was challenging to analyze cystatin C in stimulated saliva samples as we 
found lower levels than expected. Timing of saliva collection, saliva collection method and different 
drugs taken by MI patients might have affected the salivary cystatin C levels. There are no previous 
studies relating cystatin C analysis in saliva of MI/CVD patients. Further studies are needed to 
investigate the diagnostic potential of salivary cystatin C in MI patients. In addition, we correlated 
cystatin C levels to periodontal status of the study population. The levels of cystatin C showed a weak 
negative correlation with dental plaque in both groups, with gingival inflammation in non-MI group. 
Earlier studies relating to salivary cystatin C in patients with periodontal disease revealed that 
gingivitis and periodontitis patients had higher levels of cystatin C in whole and parotid saliva 
compared to healthy controls (107,108), and periodontal treatment reduced the cystatin C levels in 
whole saliva (109). The explanation for these contradictory results could be that in our study 
population, they might had a lower severity of periodontitis. 
Troponins in plasma are considered as the golden standard for diagnosis of MI. In our study (a pilot 
work, merely consist of 25 saliva samples of MI patients), we opted to use a same routine method for 
analysis of Tn I in blood for the analysis of saliva but we were unable to detect any Tn I levels in 
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stimulated saliva samples. This might be explained by the timing of the saliva sampling (eight to ten 
weeks after the onset of AMI) or due to the fact that Tn I might actually be undetectable in saliva. In 
general, Tn I levels reached their peak within 10 to14 hours after an AMI. Increased troponin levels in 
plasma can be measured up to two weeks after an infarction. Previous investigations have revealed 
that salivary cardiac biomarkers can be used in the assessment of cardiac ischemia/necrosis (110,111).  
Miller and co-authors analyzed Tn I in serum and unstimulated whole saliva collected from 92 AMI 
patients within 48 hours of chest pain onset and compared with healthy controls. The results from 
their study demonstrated that serum Tn I was the marker that was mostly associated with AMI. In 
saliva, Tn I levels were detectable in MI patients but it did not reach a significant level between AMI 
patients and controls (110). In another study, the authors used both stimulated and unstimulated whole 
saliva and serum from 30 AMI patients and 28 healthy individuals to detect Tn I levels (111). Saliva 
samples were obtained 12 and 24 hours after AMI. This investigation showed that in patients with 
AMI, serum and unstimulated saliva levels of Tn I, at both 12 and 24 hours of onset, were 
significantly higher than in controls. In addition, Tn I levels in AMI patients correlated significantly 
with serum and unstimulated saliva (111). In our study, we used an ELISA kit to analyze Tn I levels 
since Tn I levels were undetectable in the routine analyses but even with this method we were unable 
to detect Tn I levels in saliva (data not presented; a pilot work, consist of 20 saliva samples of MI 
patients). Further, in our study population, we experienced the same results when analyzing Tn T 
levels in stimulated saliva (data not reported). In both of the above referred studies (110,111), they 
used unstimulated saliva samples for Tn I detection and saliva samples were collected within few 
hours after onset of AMI. Unfortunately, in these two studies there were lacks of information 
regarding the oral status of the participants.  
In our study, salivary NT-proBNP was measured using a highly sensitive routine method (Immulite 
2000 XPi) the mean salivary NT-proBNP levels from MI patients were very low compared to plasma 
levels of NT-proBNP. In a previous study, salivary NT-proBNP was determined using AlphaLISA
(R)
 
immunoassay in patients with heart failure and healthy controls. The study was carried out to see 
whether NT-proBNP could be detected in saliva of patients with heart failure, and whether salivary 
levels correlated with plasma levels. The authors revealed that NT-proBNP could be detected in saliva 
of patients with heart failure but could not detect it in saliva samples from healthy controls. 
Furthermore, there was no correlation between salivary NT-proBNP and plasma NT-proBNP 
concentrations in heart failure patients (112) and this was in line with our results. In our study and the 
study performed by Foo et al.  it is important to consider that the measurements of NT-proBNP were 
based on two different conditions, previous MI and heart failure respectively. However, in MI patients 
who reported being stressed at work had higher salivary levels of NT-proBNP.  
Same pattern seen for NT-proBNP were also found for GDF-15 levels in saliva. The levels of GDF-
15 were lower in saliva compared to plasma but in plasma GDF-15 levels were significantly elevated 
in MI patients compared to healthy controls. Despite of that, GDF-15 in saliva showed a weak but 
significant association with gingival and periodontal inflammation in both patients and controls. This 
demonstrates that periodontal health status has to be considered when analyzing GDF-15 in saliva 
samples and also in plasma.  
Limited numbers of previous studies have demonstrated correlations between serum and salivary 
biomarkers of CVD (113,114). The medications used in the context of cardiovascular disease could be 
a possible explanation for the lack of correlation between salivary and plasma levels in our study. In 
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addition, the results could also have an affect due to saliva collection method together with timing of 
saliva sampling. 
 In Study IV, we examined following salivary biomarkers; MMP-8 and -9, MPO, TIMP-1 and the 
ratio of MMP-8 and -9/ TIMP-1 in previous MI patients and non-MI subjects with or without 
periodontal disease. MMP-8 is involved in periodontal disease progression and CVD. Earlier studies 
have reported that MMP-9 and MPO in plasma were associated with an increased risk, the onset and 
prognosis of CVD, particularly MI (115,116). In our study, salivary levels of MMP-8 and MPO were 
slightly higher in the non-MI group. This result differs to some extent from earlier studies. Furuholm 
et al. (117) showed that patients referred for open heart surgery had significantly higher salivary 
concentrations of MMP-8 compared to matched controls. No information about the reason for the 
open heart surgery or medication taken was given (117). A recent study, showed a lower 
concentration of MMP-8 in saliva, collected three to four days after the infarction from MI patients, 
which is in line with our findings (118). However, the same study also showed that the percentage of 
active MMP-8 was significantly higher in MI patients (118). This was not the case in our study, where 
we saw a tendency of more active MMP-8 in the non-MI group, despite using exactly the same 
techniques and anti MMP-8 antibody as Buduneli and co-authors. Further, the ratio of MMP-8 and -9/ 
TIMP-1 were marginally higher in MI patients but it did not reach a significant level. In another 
study, several inflammatory mediators in serum of patients with aortic sclerosis, related to severity of 
CVD were studied, and they detected elevated general MMP expression, and MMP-9 and TIMP-1 
had a positive correlation with each other (119). In our study, MMP-9 correlated positively with 
MMP-8, MPO and the ratio of MMP-8 and -9/TIMP-1 but had a negative correlation with TIMP-1 
levels. In previous animal studies, TIMP-1 has been shown to inhibit both the activity of MMP-9 
during infarct healing and in the protection against infarct plaque rupture after AMI (120). MPO in 
plasma was associated with an increased risk of CVD (115).
 
To our knowledge, there are no studies of 
salivary MPO in relation to MI, and our results showed that MPO in saliva strongly correlated with 
salivary MMP-8 and the ratio of MMP-8/ TIMP-1. According to previous reports, MPO exerted 
distinct protective role during inflammation, such as inactivation of pathogenic microbes and 
oxidative activation of latent proMMP-8 and -9 and inactivate TIMPs (60,121).
  
Furthermore, we 
correlated the analyzed salivary biomarkers with periodontal status and smoking in both study groups. 
There was a weak but significantly positive correlation between most of the analyzed biomarkers and 
the registered clinical variables in both study groups. A negative correlation between TIMP-1 and 
clinical variables was noted but TIMP-1 correlated positively with smoking and it also reached a 
significant level in both groups. Furuholm and co-authors suggested that increased salivary levels of 
MMP-8 reflected periodontal disease activity in patients with coronary artery disease (CAD) 
compared to systemically healthy controls (117).
  
Buduneli et al. and Mäntylä et al. suggested it may 
also reflect systemic inflammation, such as AMI (118,122).
 
 An earlier study demonstrated the GCF 
levels and associations between MPO and MMP-8 were related to development and treatment 
responses in patients with chronic periodontitis. The authors concluded that there was an interaction 
between the MPO oxidative pathway and MMP-8 activation, and this cascade might be useful as a 
potential biomarker for assessment of treatment outcomes (121). 
One of the important risk factors of periodontitis is tobacco smoking. Our results from Study I showed 
that mean salivary IL-8 levels, MMP-8/TIMP-1 ratio and total protein concentration were 
significantly lower in smokers compared to non-smokers. Mean levels of TIMP-1 and lysozymes 
were enhanced in smokers. MMP-8/TIMP-1 ratio was low in smokers and a possible explanation 
could be that smoking down-regulated or reduced the expression and degranulation of MMP-8 by 
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non-neutrophil- lineage cells and neutrophils, respectively (123). The results in Study IV showed that 
smoking correlated positively with TIMP-1 levels both in MI and non-MI subjects. In addition, in the 
non-MI group, MMP-9 correlated significantly with smoking whilst the ratio MMP-9/ TIMP-1 had a 
negative correlation with smoking. The impact of smoking on salivary biomarkers of periodontal 
disease may be explained by a direct effect on inflammatory cells and through their presence and 
activity, as well as a decreased flow of GCF in smokers leading to a decreased influx of inflammatory 
mediators into saliva (124).  
Salivary biomarkers could be influenced by different medications. The discrepancy between the 
findings in our studies and previous studies could be due to the medication taken by our study 
populations. The subjects in Studies I and II with muscle and joint diseases were taking a number of 
analgesics, as well as immunosuppressive agents. Agents, such as non-steroidal anti-inflammatory 
drugs, paracetamol and opioids, are commonly used to treat chronic pain and inflammation could 
potentially interfere on the expression of certain biomarkers. Nevertheless, it is known that drugs like 
monoclonal anti-TNF medication and disease-modifying anti-rheumatic drugs exert various effects on 
salivary IL-1β, TNF-α and MMP-8 levels, including reducing and no effects respectively (125). The 
patients in Studies III and IV were taking a number different medications, such as statins, angiotensin-
converting enzyme (ACE) inhibitors, beta blockers, anti-inflammatory drugs and thrombocyte 
inhibitory agents that could exert an effect on salivary cardiac and inflammatory biomarkers. 
According to previous studies, ACE inhibitors and statins potentially interfere on the expression of 
MPO, MMP-8 and -9. Some ACE inhibitors decrease the levels of MMP-9 both in acute and chronic 
phases of systemic conditions. Mechanisms of specific statins include reduction of MMP-9 levels 
(126,127). 
A number of definitions of periodontal disease have been used in the literature over the years (16, 
128-130), which was reflected in our study as well. In the Skåne cohort (Studies I and II), the study 
population was divided into three groups based on their periodontal disease experience. The groups 
were divided based on the amount of marginal bone loss around each remaining tooth and the 
periodontal diagnosis in this project was based entirely on radiographic assessment. The study 
population of PAROKRANK sub-cohort (Studies III and IV), periodontal diagnosis was based on 
clinical periodontal examination only.  It is recommended to use both clinical examination and 
radiographic assessments for periodontal diagnosis. There is a higher risk to obtain false positive and 
negative results by using either clinical status or radiographic evaluation.  
 
General aspects on strengths and limitations: 
There are some important methodological considerations that have to be considered in relation to our 
findings. In Studies I & II, study design was cross-sectional, which comprised of cases and control 
individuals. Thus, there was potential selection and information bias, and it is recognized that the 
control individuals came from the same population base. Moreover, the medical status was 
retrospectively collected, which was based on the participants’ self-assessment and no verification of 
answers from anamnestic data.  There could be a risk for false negatives, for instance undiagnosed 
diseases. In Studies III and IV, we collected data eight to ten weeks after exposure of an AMI and the 
post MI condition of the patients, including drugs used by the MI-group eventually exerted an effect 
on the analyzed biomarkers. There were many investigators (both dentists and dental hygienists), who 
performed dental examinations of the study population, which is a negative point, as it could affect 
the outcome of clinical examinations. Another limitation is that periodontal classification of the study 
population in this sub-cohort of the PAROKRANK project was merely based on clinical periodontal 
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parameters and not together with radiographical assessment. Further, it was important to consider that 
the numbers of participants are limited in this sub-cohort. 
 
In both cohorts, the results might have been affected by the pre-analytical procedures for saliva 
samples and the methods/ kits used for salivary analyses might not be highly sophisticated. However, 
there are both advantages and disadvantages to using biochemical methods for analyzing purposes. 
ARCHITECT i4000SR SYSTEM (Abbott) and Immulite 2000 XPi (Siemens, Diagnostic Product 
Corporation) are highly sensitive and gold standard routine methods for blood analyses of Tn I and 
NT-proBNP respectively. We have used both methods (ARCHITECT i4000SR SYSTEM: Tn I) and 
(Immulite 2000 XPi: NT-proBNP) for analysis in stimulated saliva samples. Antibodies used in both 
assays were very specific. These are automated methods, and systematically errors are obtained very 
rarely compared to other immunochemistry methods. Although both of the above mentioned methods 
are highly sophisticated, there could be a minimal risk to obtain analytical interference, which could 
distract antibodies in vitro immunoassays.  
Bradford protein assay, ELISA, Luminex and IFMA assays, and Western blot are immunochemistry 
methods, are standardized and widely used in research laboratories. IFMA is a highly sensitive and 
sophisticated method compared to ELISA and Luminex methods. Luminex assays are a good choice 
for multiple analytes but these assays are less sensitive than ELISA assays. Western blot is a widely 
used analytical technique to detect specific proteins in a sample/ tissue/ extract. It is significant to 
consider that there are some limitations of using the above mentioned analytical techniques, even 
though reagents are formulated to minimize the risk of interference, the potential interactions with in 
vitro immunoassays and test components can occur, and well-trained laboratory assistants are needed 
to handle the samples to acquire good results.   
Strength with the Skåne cohort is the large size, including 400 patients. Furthermore the periodontal 
diagnosis was based on radiographic assessments performed by few investigators. Major strength in 
PAROKRANK study is the carefully matching of cases and controls and cases were included at the 
occasion of a first MI, minimizing interactions of other compounding diseases and complications. The 
timing of the blood and saliva collections, eight to ten weeks after the MI, could in some context, be 
regarded as a strength, minimizing the acute stress response on inflammatory markers and other 
prognostically important biomarkers. Future studies, will address such circumstances.  
  
 
FUTURE IMPLICATIONS 
 
Salivary diagnostics is an evolving research area. Biomarkers found in saliva are mainly from plasma, 
serum, GCF and mucosal transudate, which infiltrate saliva due to oral and/systemic diseases.  Highly 
sophisticated techniques are needed to provide the sensitivity and specificity for accurate and 
reproducible disease diagnosis. For example, to identify key molecules that appear in saliva during the 
processes of different conditions/ diseases is critical to the field of salivary diagnostics. The utility of 
saliva as a diagnostic tool will only be achieved once key biomarkers are validated in longitudinal 
studies. 
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Biomarkers related to inflammation, tissue destruction and bone remodeling associated with 
periodontitis appear in saliva but the evidence is insufficient in both stimulated- and unstimulated 
saliva. Clinical examination and radiographical assessments are standard procedures of diagnosis of 
periodontitis however there is a lack of investigations including patients with different periodontal 
disease phases. Future studies should aim to include patients with different phases of active disease to 
be able to identify more specific disease biomarkers in saliva. An easily fast taken saliva sample 
might be an attractive medium to traditional time consuming clinical diagnosis procedures of 
periodontal disease by offering some distinct advantages for screening, monitoring and detection. 
 
Cardiac related biomarkers, in particular inflammatory markers, plaque adhesion/rupture and tissue 
necrosis are at insignificant levels in saliva during early hours after onset of an acute MI but the 
evidence is not robust and there is a lack of information regarding oral status in previous studies. AMI 
is a condition, which needs immediate therapy, salivary diagnostics might be perfect for a fast early 
detection but additional studies are required to evaluate salivary cardiac related markers measured in 
samples collected at the time of admission to identify an acute coronary event. Troponin levels in 
saliva were at insignificant levels eight to ten weeks after a MI. Before troponin levels are 
discouraged as a screening biomarker in saliva, further investigations are needed, including analyses 
of both stimulated and unstimulated saliva since troponin levels are measurable in saliva over the first 
hours of an AMI.  
 
Certain salivary biomarkers, such as IL-1β, and -8, GDF-15, NT-proBNP and MMP-8 are highly 
measurable in whole saliva.  Theses markers could therefore be highly interesting as screening 
markers in saliva, since all of them are related to conditions, such as cardiovascular disease and 
cancer. For instance elevated inflammatory markers as IL-8 correlate with an unspecific cancer 
diagnosis.  Further studies are needed to develop key molecular biomarkers that correlated to a more 
specific cancer diagnosis. 
 
Furthermore, type of saliva; stimulated or unstimulated will have a significant effect on salivary 
biomarker composition and analysis and this needs to be taken in to consideration when using saliva 
for diagnostic/ screening purposes.  
 
Future developments in salivary diagnostics for screening, risk assessment and therapeutic 
management for a range of conditions are promising and this approach will hopefully allow 
individualized treatments before arise of major clinical symptoms.  
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CONCLUSIONS 
 
 
 Salivary IL-1β, MMP-8 and the ratio of MMP-8/TIMP-1 could be used as markers for 
periodontal disease in larger patient populations. 
 
 Salivary IL-8 concentration was found to be remarkably high in subjects who had experienced 
tumor diseases and bowel disease. MMP-8 levels were elevated in stimulated saliva from 
patients after cardiac surgery or suffering from diabetes. The levels of IL-1β, IL-8 and MMP-
8, as well as the MMP-8/TIMP-1 ratio were higher in subjects with muscle and joint diseases. 
 
 Salivary GDF-15 levels correlated with periodontal status of MI-patients and controls, and the 
levels of cystatin C, NT-pro BNP and GDF-15 in saliva were higher in MI patients with other 
co-morbidities. The analyzed cardiac related biomarkers seem to be in very low 
concentrations in stimulated saliva and do not correlate to plasma levels.  
 
 Tn I levels in stimulated saliva were undetectable.  
 
 Salivary MMP-8 and -9, MPO, TIMP-1 and ratio of MMP-8, -9/ TIMP-1 correlated with each 
other and with periodontal parameters in both patients with or without previous MI.  
 
 Saliva-based clinical testing could provide a future potential diagnostic tool for the detection 
of certain diseases/ conditions using biomarkers associated with enhanced oral and systemic 
inflammation but when evaluating biomarkers in saliva the influence of both systemic and oral 
health should be considered. 
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